洛铂联合卡培他滨治疗22例晚期乳腺癌的临床观察

目的 观察洛铂联合卡培他滨治疗晚期乳腺癌的疗效和不良反应。方法 22例晚期乳腺癌患者均采用洛铂联合卡培他滨方案治疗，具体如下：洛铂30mg／m2静滴3h，d1；卡培他滨2500mg／m2，每日分2次口服，d1～d14。3周为1个周期。按照RECIST 1.0版标准评价疗效以及WHO急性及亚急性毒性标准评价不良反应。结果 全组22例患者中，无1例获CR，获PR 9例，SD 8例，PD 5例；有效率为409％，疾病控制率为773％。中位无进展生存时间为8.9个月，中位总生存时间为14.2个月，1年生存率为72.7％。主要不良反应为胃肠道反应、骨髓抑制和手足综合征，均以1～2级为主。结论 洛铂联合卡培他滨治疗复发转移性乳-腺癌的疗效较好，不良反应轻，值得临床推广。

Clinical observation of lobaplatin plus capecitabine in treating 22 advanced breast cancer patients

Objective To evaluate the efficacy and adverse effects of lobaplatin plus capecitabine in the treatment for ad- vanced breast cancer. Methods Twenty-two patients with advanced breast cancer accepted lobaplatin plus capecitabine chemothera- py. Lobaplatin 30mg/m^2 iv 3h, d1 ; capecitabine 2500mg/m^2 for twice daily 30min after meal with oral administration, d1-d14. Three weeks was a cycle. Objective response was evaluated by RECIST 1.0 standard and adverse effects were evaluated by WHO standard. Results In the 22 patients, no one got CR, with 9 of PR, 8 of SD and 5 of PD. The objective response rate was 40. 9% and the dis- ease control rate was 77. 3%. The median progression-free survival was 8.9 months and the median overall survival was 14. 2 months. The main adverse effects were gastrointestinal reaction, bone marrow suppresion and hand-foot syndrome, mainly in grade 1-2. Con- clusion Lobaplatin plus capecitabine regimen is effective and well tolerated for advanced breast cancer, worthy of further clinical study.